Escolar Documentos
Profissional Documentos
Cultura Documentos
Introduction
Asthma is a disorder that affects the airways of the lungs and causes difficulty in
breathing. It is increasing in prevalence. The exact cause of asthma is not known. While
there are a large number of drugs available for treating asthma, they are primarily
palliative therapies. There is no cure for asthma. A combination of drugs may be needed
to manage symptoms in most patients.
Definition
The definition of asthma has evolved from several consensus documents. The most recent
definition is that of the Global Initiative for Asthma GINA (2003) (http://www.ginasthma.
com/). Asthma is a chronic inflammatory disorder of the airways in which many cells and
cellular elements play a role. The chronic inflammation causes an associated increase in
airway responsiveness (hyperreactivity) that leads to recurrent episodes of wheezing,
breathlessness, chest tightness, and coughing, particularly at night or in the early morning.
These episodes are usually associated with widespread, but variable airflow obstruction
that is often reversible either spontaneously or with treatment.
Airflow decrements arise from bronchoconstriction, swelling of the airway wall, alteration in the quality and quantity of mucus, including formation of mucus plugs and
remodeling Holgate and Davies (2000) of the airways. Abnormally high levels of IgE
antibodies in response to common allergens are seen in many, but not all, asthmatic
patients.
Status asthmaticus (near-fatal asthma) is a very severe form of asthma attack that may
lead to death. Mucus plugging, airway edema, and bronchoconstriction severely limit
airflow, and restrict airway mechanics and gas exchange.
Exercise-induced asthma, a misnomer for exercise-induced airway obstruction, may
occur in asthmatic patients. Exercise does not cause asthma, but a decrement in airflow
may occur in asthmatic patients who exercise.
Asthma may be caused or exacerbated by substances inhaled in the environment.
Terms used to describe this condition are occupational asthma or work-related asthma.
Steroid-resistant asthma and difficult asthma represent more severe manifestations of
the disease.
Classification
Asthma is a chronic obstructive lung disease. Other chronic obstructive pulmonary
diseases (COPD) include emphysema and chronic bronchitis.
Asthma, left untreated, may progress in severity. Classification of asthma by steps is
based on the severity of the disease. A given patient may move between steps. The most
accepted classification of asthma is that promulgated by the Global Initiative for Asthma
GINA (2003) (http://www.ginasthma.com/). Therapeutic choices are based on the
1
Asthma
Consequences
Some children outgrow their childhood asthma after adolescence. However, approximately 50% of the population carries asthma into adulthood. Periods of remission occur
in children and adults.
While asthma causes substantial morbidity, it does not cause significant mortality. Most
of the deaths are considered preventable and require identification of a worsening clinical
condition with subsequent use of efficacious drugs. Left untreated, status asthmaticus
places a patient at high risk of death by asphyxiation.
Associated Disorders
Asthma is often associated with atopy, which may give rise to conjunctivitis, eczema,
allergy, and rhinitis. Allergic rhinitis accompanies asthma in many children. Often,
treatment of the associated disorder improves the asthmatic condition.
Asthma
Etiology
Asthma attacks, including those that can lead to status asthmaticus, may be provoked by
allergen exposure and challenge, for example to indoor allergens such house dust mites
and outdoor allergens such as pollen; respiratory infections; air pollutants; chemicals;
aspirin; weather (cold and dry air); menstruation; emotional stress; and exercise. Asthma
is a complex condition involving many pathophysiological changes. The greatest risk
factor for the development of asthma is atopy, with increased levels of circulating Ig
E. However, asthma may exist in nonatopic individuals. Asthma tends to be familial,
suggesting a genetic predisposition Barnes (2000a) exists for the development of the
disease. Atopy, airway responsiveness, and IgE are thought to have heritable components.
Recently, a gene (ADAM33) for metalloproteases found on chromosome 20p13 was linked
to asthma and airway hyperreactivity Van eerdewegh et al (2002). Environmental factors
may predispose individuals toward establishment of asthma Anderson and Cookson
(1999), Cookson (1999). Near fatal attacks of asthma (status asthmaticus) may be precipitated by a variety of causes, including exposure to allergen, air pollutants, respiratory
tract infections, emotional stress, weather, noncompliance with medications, and aspirin
or other nonsteroidal anti-inflammatory drugs. The cause of exercise-induced asthma
(obstruction) is not understood. However, it is hypothesized that drying of the airway
surface during hyperventilation, and the subsequent increase in osmolarity, may trigger
hyperemia in the airway wall and the release of mast cell mediators, such as histamine and
leukotrienes, which cause bronchoconstriction. Cool, dry air inhalation is a greater
stimulus to exercise-induced obstruction than warm, humid air.
Epidemiology
In 2001, 14 million adults and 6.3 million children were considered asthmatic. Approximately 4.3 million children (5.7%) had an asthma attack. There were 4,269 deaths from
asthma (1.5 per 100,000) in 2001 and 1.8 million visits to the emergency room for asthma
in 2000.
Exercise-induced asthma (obstruction) occurring during or after exercise is experienced by approximately 90% of asthmatic patients and 12% of the general population.
The prevalence of asthma is increasing. The frequency of asthma among children in
developed countries is being referred to as a pediatric epidemic. In children younger than
10 years, males have increased incidence compared to females. However, more adult
women are affected by asthma than men. The prevalence of acute asthma in AfricanAmerican and Hispanic populations in the United States exceeds that of Caucasians
Rhodes et al (2004).
Asthma outcomes are worse in underserved minority groups.
It has been hypothesized (hygiene hypothesis) that in Western countries atopy is
correlated with a decline in common infections and an improvement in hygiene. This
favors differentiation of the Th2 cell lymphocyte subtype (the asthma phenotype) over
the Th1 cell type.
Pathophysiology
A predominant feature of asthma is inflammation of the airways. The effects of asthma
result from complex and self-sustaining interactions between several inflammatory cell
types and their released mediators, including epithelial cells, dendritic cells, mast cells,
Asthma
Th2 cells, neutrophils, myofibroblasts Holgate and Davis (2000), and neuropeptidecontaining sensory nerves.
Eosinophils are implicated in the disease process because of the toxicity of proteins
contained in their large, dense core granules, e.g., major basic protein. Major basic protein
may be primarily responsible for the damage to and sloughing of airway epithelium
throughout the asthmatic airway. Eosinophils are elevated in the airway wall during
late-phase asthmatic responses.
Inflammatory cells and their mediators bring about a number of changes in the airway
wall, including:
(1) Nonspecific airway hyperreactivity to bronchoconstrictors (greater than normal
bronchoconstrictive response to inhaled drugs such as methacholine and histamine)
(2) Airway smooth muscle contraction (bronchoconstriction)
(3) Microvascular leakage and submucosal edema
(4) Thickening of the reticular basement membrane
(5) Smooth muscle hypertrophy (along with basement membrane thickening, this results
in thickening of the airway wall)
(6) Increased vascularization of the lamina propria (increase in the number and size of
blood vessels)
(7) Damage to and sloughing of airway epithelium
(8) Squamous and goblet cell proliferation
(9) Hypersecretion of a thick, tenacious mucus
(10) Mucus plugging
(11) Increased sputum production
The principle mediators Barnes et al (1998), Toews (2001), Riffo-Vasquez and Spina
(2002) involved in the inflammation include lipid products (leukotriene B4, leukotriene
C3, leukotriene D4 and leukotriene E4); prostaglandins (E2, F2a, D2); platelet activating
factor, peptides (bradykinin, endothelin, neuropeptides), a multitude of TH2 cytokines
(IL-3, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13) and other potent chemotactic peptides
(RANTES, eotaxin) Wenzel (2003), Riffo-Vasquez and Spina (2002), Toews (2001),
Barnes et al (1998).
Inhaled adenosine, cyclic AMP (cAMP), and hypertonic solutions (NaCl or Dmannitol) elicit bronchoconstriction in asthmatic patients but not nonasthmatic individuals. The mechanisms and significance of the response to inhaled adenosine and cyclic
AMP is not clear, but the effects of hypertonic solutions may bear some relationship to the
changes in airway surface liquid osmolarity that may stimulate exercise-induced obstruction. Interestingly, asthmatic patients may also experience obstruction upon inhalation of
hypotonic solutions.
Inhalation of an allergen to which the asthmatic patient is already sensitized leads to an
early phase and a late phase bronchoconstriction. These may vary in their intensities. The
early phase is immediate in onset and resolves within a few hours. The late phase develops
3 to 12 hours later and is accompanied by an inflammatory response in the airway wall and
airway hyperreactivity. The early phase is IgE-dependent and is thought to result from
degranulation of mast cells and the liberation of histamine, leukotrienes, and other
mediators, which then stimulate the inflammatory response associated with the late
phase. In an acute attack, therapy is directed at control of the late phase response. Therapy
for chronic asthma is directed toward prevention of both phases. Because both phases
involve contraction of airway smooth muscle, bronchodilator agonists that cause relaxation of the muscle are effective for treating bronchoconstriction in either phase, but they
are ineffective at stemming the inflammatory response of the second phase.
Asthma
Standard Therapies
Goals of asthma therapy
The intensity and plan of therapy, and the ability to reverse the pathophysiological
changes in the asthmatic patient, are related to the severity of the disease. Generally,
the goals are to: 1) normalize lung function, 2) decrease airway hyperresponsiveness, 3)
prevent exacerbation of symptoms and, 4) minimize drug side effects.
Asthma
Discussion
Beta-2 adrenoceptor
agonists
Epinephrine
Methyl xanthines
Asthma
Anticholinergics
Glucocorticoids
Cromones
Asthma
Leukotriene receptor
antagonists
5-Lipoxygenase
inhibitors
Omalizumab
Experimental Therapies
The search for new anti-asthma medications is stimulated by the inadequacies of the
current agents. The etiology of asthma is complex, and involves a large number of pathways
and mechanisms. Ideally, an asthma cure will be discovered. Until that time, new
therapies will provide flexibility in therapeutic approaches while decreasing side effects.
Asthma
Agent Name
Discussion
Phosphodiesterase 4
inhibitors
Alternative therapies
Animal Models
No animal model has been developed that recapitulates all the hallmarks of human
asthma. Invariably, the many models that have been developed in several species involve
sensitization with a foreign antigen and re-challenge later with inhaled antigen. The
inhaled antigen generally provokes an immediate and a late phase response, and the
mediators involved in both phases resemble those involved in the human disease, as
judged by the effects of pharmacological blockers. Inflammation of the airways is usually,
but not always, produced, but the relationship between inflammation and airway hyperreactivity is not unequivocally established. The subject of asthma animal models has been
reviewed Vargaftig (1999), Abraham (2000), Bice and Seagrave (2000), Szelenyi (2000). As
examples, investigators have noted altered mucin gene expression in guinea pigs Li et al
(2001), lung remodeling in mice Tanaka et al (2001), and smooth muscle hypertrophy in
rats Moir et al (2003).
10
Asthma
www.harrison.accessmedicine.com/
www.search.nlm.nih.gov/medlineplus/ (search using term: asthma)
www.intelihealth.com/IH/ihtIH/WSIHW000/408/408.html (search using term:
asthma; this is a site for lay audiences)
www.fpnotebook.com/LUNCh4.htm (This site is very comprehensive and allows efficient
searching.)
This site from the American College of Chest Physicians contains material presented at
the postgraduate level: www.chestnet.org/cgi-bin/search/x/search.pl?Realm=All&Match
=1&Terms=asthma&nocpp=1&Rank=41
Journal Citations
Anderson, G.G., Cookson, W.O.C.M., 1999. Recent advances in the genetics of allergy and asthma. Mol.
Med. Today, 5, 264273.
Barnes, K.C., 2000a. Atopy and asthma genes-where do we stand. Allergy, 55, 803817.
Barnes, P.J., Chung, K.F., Page, C.P., 1998. Inflammatory mediators of asthma: An update. J. Pharmacol.
Exp. Therap., 50(4), 515596.
Barnes, P.J., 2000b. Anti-IgE therapy in asthma: Rationale and therapeutic potential. Internat. Arch. Allergy
Immunol., 123, 196204.
Bice, D.E., Seagrave, J., 2000. Animal models of asthma: Potential usefulness for studying health effects of
inhaled particles. Inhal. Tox., 12, 829862.
Bryan, S.A., Leckie, M.J., Hansel, T.T., Barnes, P.J., 2000. Novel therapy for asthma. Expert Opinion on
Investigational Drugs, 9(1), 2542.
Campillo, N., Paez, J.A., 2002. Novel bronchodilators in the treatment of asthma and COPD. Expert Opinion
on Therapeutic Patents, 12(1), 5362.
Cookson, W., 1999. The alliance of genes and environment in asthma and allergy. Nature, 402(suppl. 25),
B5B11.
Chang, T.W., 2000. The pharmacological basis of anti-IgE therapy. Nature Biotech., 18(2), 157162.
Childhood Asthma Management Program Research Group (CAMP) Long-term effects of budesonide or
nedocromil in children with asthma 2000 N. Eng. J.Med., 343, 10541062.
Van eerdewegh, P., Little, R.D., Dupuis, J., et al., 2002. Association of the ADAM33 gene with asthma and
bronchial hyperresponsiveness. Nature, 418, 426430.
Giembycz, M.A., 2000. Phosphodiesterase 4 inhibitors and the treatment of asthma: Where are we now and
where do we go from here. Drugs, 59(2), 193212.
Holgate, S.T., Davies, D.E., 2000. Airway inflammatory and remodelling in asthma-cause and effect.
Immunologist, 8(6), 131135.
Holtzman, M.J., 2003. Drug development for asthma. Amer. J.Resp. Cell and Mol. Biol., 29, 163171.
Ito, K., Caramori, G., Lim, S., Oates, T., Chung, K.F., Barnes, P.J., Adcock, I.M., 2002. Expression and
activity of histone deacetylases in human asthmatic airways. Amer. J. Resp. Critical Care Med., 166,
392396.
Li, Y., Martin, L.D., Minnicozzi, M., Greenfeder, S., Fine, J., Pettersen, C.A., Chorley, B., Adler, K.B., 2001.
Enhanced expression of mucin genes in guinea pig model of allergic asthma. Amer. J.Resp. Cell and Mol.
Biol., 25, 644651.
McFadden, E. R. Jr, 2003. Acute severe asthma. Amer. J. Resp. Critical Care Med., 168, 740759.
Milgrom, H., Fick, R.B. Jr, Su, J.Q., Reimann, J.D., Bush, R.K., Watrous, M.L., Metzger, W.J., 1999.
Treatment of allergic asthma with monoclonal anti-IgE antibody. N. Eng. J. Med., 341(26), 19662008.
Moir, L.M., Leung, S.Y., Eynott, P.R., McVicker, C.G., Ward, J.P., Chung, K.F., Hirst, S.J., 2003. Repeated
allergen inhalation induces phenotypic modulation of smooth muscle in bronchioles of sensitized rats.
Amer. J. Physiol.. Lung Cellular and Molec. Physiol., 284, L148L159.
Niven, A.S., Argyros, G., 2003. Alternate treatments in asthma. Chest, 123, 12541265.
Pahl, A., Szelenyi, I., 2002. Asthma therapy in the new millennium. Inflam. Res., 51, 273282.
Rhodes, L., Bailey, C.M., Moorman, J.E., 2004. Asthma prevalence and control characteristics by race/
ethnicity-United States, 2002. Morbid. Mortal. Weekly Rep., 53(7), 145148.
Riffo-Vasquez, Y., Spina, D., 2002. Role of cytokines and chemokines in bronchial hyperresponsiveness
and airway inflammation. Pharmacol. Therap., 94, 185211.
Szelenyi, I., 2000. Animal Models of bronchial asthma. Inflam. Res., 49, 639654.
Tanaka, H., Masuda, T., Tokuoka, S., Komai, M., Nagao, K., Takahashi, Y., Nagai, H., 2001. The effect of
allergen-induced airway inflammation on the airway remodeling in a murine model of allergic asthma.
Inflam. Res., 50, 616624.
Toews, G.B., 2001. Cytokines and the lung. Euro. Res. J., 18, 3S17.
Vargaftig, B.B., 1999. What can we learn from murine models of asthma. Clin. Exper. Allergy, 29(suppl. 1),
S9S13.
Asthma
Wenzel, S.E., 2003. The role of leukotrienes in asthma. Prostaglandins, Leukotrienes and Essential Fatty
Acids, 69, 145155.
Drazen, J.M., Israel, E., OBryne, P.M., 1999. Treatment of asthma with drugs modifying the leukotrine
pathway. N. Eng. J. Med., 340, 197206.
Book Citations
Abraham, W.M., 2000. Animal Models of Asthma. Busse, W.W., Holgate, S.T. (Ed.), Asthma and Rhinitis,
Edition 2, pp. 12051227, Blackwell Science Ltd, Oxford.
GINA 2003 Global Initiative for Asthma. Global strategy for asthma management and prevention. NIH
Publication No 02-3659.
Further Reading
Anon., British guidelines on the management of asthma, Thorax, 58(Suppl 1) (1996) S1S92
Barnes, P.J., Grunstein, M.M., Leff, A. R. and Woolcock, A.J., Asthma, Lippincott-Raven, Philadelphia,
1997
Busse W. W. and Holgate, S.T., Asthma and Rhinitis, Blackwell Science, Oxford, 2000
Global Initiative for Asthma. Global strategy for asthma management and prevention. NIH Publication No
023659, 2003. (This volume is also available at www.ginasthma.com).
Textbook of Respiratory Medicine, J. F. Murray, J. A. Nadel, R. J. Mason and H. A. Boushey (Eds.),
W. B. Saunders, Philadelphia, 2000
11